“Pharmacoeconomic comparison of ziprasidone with other atypical oral antipsychotic agents in schizophrenia” (2011) Farmeconomia. Health economics and therapeutic pathways, 12(1), pp. 29–40. doi:10.7175/fe.v12i1.96.